Environmental

Low Direct Environmental Footprint: Exelixis operates as a biotechnology company with limited manufacturing and a focus on R&D, resulting in a relatively low direct carbon and resource footprint compared to peers in heavy manufacturing or large-scale pharma production.

Sustainability Reporting and Transparency: The company provides basic disclosures on environmental practices but lacks comprehensive, quantitative targets for emissions reduction or resource efficiency, which is increasingly expected among global biotech peers.

Supply Chain and Product Stewardship: Exelixis outsources much of its manufacturing, which limits direct control over supply chain emissions and environmental risks, though it maintains compliance with regulatory standards.

Exelixis’s environmental risk profile is moderate, reflecting its R&D-centric model and limited direct emissions. However, the absence of robust sustainability targets and limited supply chain oversight constrain its score relative to best-in-class biotech peers.

Social

Workforce Investment and R&D Focus: Exelixis invests heavily in research and development, with R&D expenses representing over 33.8% of revenue, supporting talent retention and innovation in oncology.

Product Impact and Patient Access: The company’s oncology drugs address high unmet medical needs, with recent approvals and pipeline progress in difficult-to-treat cancers, contributing positively to patient outcomes.

Diversity, Equity, and Inclusion (DEI): Exelixis discloses basic DEI initiatives and workforce diversity metrics, but its programs are less comprehensive than those of larger global peers.

Exelixis demonstrates strong social performance through its focus on R&D, positive patient impact, and a growing international presence. While DEI efforts are present, they are not yet industry-leading, but the company’s core mission and workforce investment drive a robust social profile.

Governance

Experienced Leadership and Board: The company is led by a long-tenured CEO and maintains a board with relevant industry expertise, supporting strategic execution and oversight.

Capital Discipline and Financial Controls: Exelixis maintains a conservative capital structure, with a debt-to-equity ratio of 0.09 and negative net debt, indicating prudent financial management and low leverage risk.

Executive Compensation and Shareholder Alignment: Stock-based compensation is moderate at 4.6% of revenue, aligning management incentives with shareholder interests, though not as tightly as some best-in-class peers.

Exelixis’s governance is solid, with experienced leadership and strong financial controls. However, board diversity and compensation alignment could be further enhanced to match leading biotech governance standards.

Overall Score

Exelixis scores strongly on ESG due to its R&D-driven social impact, prudent financial management, and low direct environmental risk. The company’s main limitations are in environmental target-setting and governance best practices, but its overall ESG profile is robust and competitive within the biotech sector.